Loading
Led the futibatinib trial and defined how FGFR2-driven bile duct cancers become resistant to targeted drugs.
Lipika Goyal was principal investigator of FOENIX-CCA2, which won futibatinib approval for FGFR2 fusion-positive cholangiocarcinoma, and used serial ctDNA to describe the polyclonal FGFR2 kinase domain mutations that drive acquired resistance to FGFR inhibitors. She directs GI oncology at Stanford and leads trials of next-generation FGFR inhibitors.
Shares FGFR2, Biliary tract cancer (cholangiocarcinoma), Small-molecule kinase inhibitors.
Shares Biliary tract cancer (cholangiocarcinoma) and the tag biliary.
Shares Stanford Health Care / Stanford Cancer Institute, Liquid biopsy (ctDNA).
Shares FGFR2, Biliary tract cancer (cholangiocarcinoma), Small-molecule kinase inhibitors.
Shares Small-molecule kinase inhibitors and the tag targeted-therapy.
Shares Biliary tract cancer (cholangiocarcinoma) and the tag biliary.
Shares FGFR2, Biliary tract cancer (cholangiocarcinoma), Small-molecule kinase inhibitors.